Mesoblast (MESO) Share-based Compensation (2016 - 2025)
Mesoblast's (MESO) quarterly Share-based Compensation came in at $15.2 million in Q2 2025, up 591.21% year-on-year from $2.2 million in Q2 2024, and up 591.21% quarter-over-quarter from $2.2 million in Q2 2024.
Mesoblast (MESO) Share-based Compensation (2016 - 2025) Analysis & Trends
Mesoblast has disclosed Share-based Compensation across 10 years of filings, most recently posting $15.2 million for Q2 2025.
- Share-based Compensation for Q2 2025 came in at $15.2 million, up 591.21% year-over-year; the trailing twelve-month figure through Jun 2025 was $13.9 million (up 2836.15% YoY), and the FY2025 annual result was $15.2 million, up 591.21% from the prior year.
- Share-based Compensation came in at $15.2 million for Q2 2025 at Mesoblast, up from $2.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $15.2 million in Q2 2025 to a low of -$6.5 million in Q1 2022.
- The 5-year median for Share-based Compensation is $2.0 million (2022), against an average of $3.2 million.
- Across the five-year window, Share-based Compensation tumbled 162.35% in 2022 and soared 591.21% in 2025, its largest moves.
- Mesoblast's Share-based Compensation stood at $2.6 million in 2021, then plunged by 31.26% to $1.8 million in 2022, then changed by 0.0% to $1.8 million in 2023, then rose by 24.93% to $2.2 million in 2024, then jumped by 591.21% to $15.2 million in 2025.
- The last three Share-based Compensation figures came in at $15.2 million (Q2 2025), $2.2 million (Q2 2024), and $1.8 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 15.17 Mn |
| Jun 30, 2025 | 15.17 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Jun 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 1.76 Mn |
| Mar 31, 2023 | -5.24 Mn |
| Mar 31, 2023 | -5.24 Mn |
| Dec 31, 2022 | 1.76 Mn |
| Dec 31, 2022 | 1.76 Mn |
| Sep 30, 2022 | 350,000.00 |
| Sep 30, 2022 | 350,000.00 |
| Jun 30, 2022 | 4.45 Mn |
| Jun 30, 2022 | 4.45 Mn |
| Mar 31, 2022 | -6.51 Mn |
| Mar 31, 2022 | -6.51 Mn |
| Dec 31, 2021 | 2.56 Mn |
| Dec 31, 2021 | 2.56 Mn |
| Sep 30, 2021 | 1.08 Mn |
| Sep 30, 2021 | 1.08 Mn |